Edition:
India

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

65.04USD
1:32am IST
Change (% chg)

$-0.06 (-0.09%)
Prev Close
$65.10
Open
$65.20
Day's High
$65.92
Day's Low
$65.02
Volume
1,685,780
Avg. Vol
2,052,219
52-wk High
$68.12
52-wk Low
$55.10

ABBV.N

Chart for ABBV.N

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology,... (more)

Overall

Beta: 1.54
Market Cap(Mil.): $103,741.80
Shares Outstanding(Mil.): 1,593.58
Dividend: 0.64
Yield (%): 3.93

Financials

  ABBV.N Industry Sector
P/E (TTM): 17.83 29.34 30.35
EPS (TTM): 3.65 -- --
ROI: 12.09 13.84 13.36
ROE: 138.75 14.77 14.50

BRIEF-Aquinnah receives $10 mln investment from Pfizer, Abbvie

* Aquinnah Pharmaceuticals receives $10 million investment from Pfizer and Abbvie to research breakthrough approach to neurodegenerative disease

25 Apr 2017

BRIEF-Enanta announces eight weeks of treatment with Abbvie's investigational drug achieved high SVR rates in challenging-to-treat genotype 3 chronic HCV patients

* Enanta announces eight weeks of treatment with Abbvie's investigational, pan-genotypic, ribavirin-free HCV regimen of glecaprevir/pibrentasvir (g/p) achieved high SVR rates in challenging-to-treat genotype 3 chronic HCV patients

21 Apr 2017

AbbVie cancer drug fails two late-stage trials

AbbVie Inc said on Wednesday that its experimental cancer drug, veliparib, failed to meet the main goals of two late-stage studies.

20 Apr 2017

UPDATE 1-AbbVie cancer drug fails two late-stage trials

April 19 AbbVie Inc said on Wednesday that its experimental cancer drug, veliparib, failed to meet the main goals of two late-stage studies.

20 Apr 2017

AbbVie cancer drug fails two late-stage trials

April 19 AbbVie Inc said on Wednesday that its cancer drug, veliparib, failed to meet the main goals of two late-stage studies.

20 Apr 2017

BRIEF-Argen X receives first preclinical milestone payment in Abbvie collaboration

* Receives first preclinical milestone payment in abbvie collaboration

13 Apr 2017

BRIEF-U.S. FDA approves addition of moderate to severe fingernail psoriasis data to Abbvie's humira

* U.S. FDA approves addition of moderate to severe fingernail psoriasis data to Abbvie's Humira (adalimumab) prescribing information

30 Mar 2017

BRIEF-Abbvie and M2Gen announce new collaboration

* Abbvie and M2Gen announce new collaboration for the oncology research information exchange network® (orien) avatar research program Source text for Eikon: Further company coverage:

28 Mar 2017

BRIEF-Abbvie CEO Richard Gonzalez's FY 2016 total compensation was $21 mln

* CEO Richard Gonzalez's FY 2016 total compensation was $21.0 million versus $20.8 million in FY 2015 - sec filing

20 Mar 2017

BRIEF-Abbvie granted priority review in Japan for its investigational regimen of Glecaprevir

* Abbvie granted priority review in Japan for its investigational regimen of Glecaprevir/Pibrentasvir (G/P) for the treatment of all major genotypes of chronic hepatitis c

14 Mar 2017

More From Around the Web

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $123.51 +0.08
Pfizer Inc. (PFE.N) $33.85 +0.09
Novartis AG (NOVN.S) CHF76.15 +0.45
Merck & Co., Inc. (MRK.N) $62.70 +0.40
Roche Holding Ltd. (ROG.S) CHF257.80 +0.80
Roche Holding Ltd. (RO.S) CHF258.50 +1.00
Abbott Laboratories (ABT.N) $43.80 +0.04
Eli Lilly and Co (LLY.N) $80.96 -0.24
Sanofi SA (SASY.PA) €85.65 --

Earnings vs. Estimates